Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro

References

• Andreone P, Colombo MG, Enejosa JV, et al. (2014). ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147:359–65.
   PubMed Web of Science ®Google Scholar
• Asahina Y, Izumi N, Hiromitsu K, et al. (2016). JSH guidelines for the management of hepatitis C virus infection: A 2016 update for genotype 1 and 2. Hepatol Res 46:129–65.
   PubMed Web of Science ®Google Scholar
• Badri PS, King JR, Polepally AR, et al. (2016a). Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet 55:275–95.
   PubMed Web of Science ®Google Scholar
• Badri PS, Dutta S, Wang H, et al. (2016b). Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir-ritonavir. Antimicrob Agents Chemother 60:105–14.
   PubMed Web of Science ®Google Scholar
• Dorr CR, Remmel RP, Muthusamy A, et al. (2017). CRISPR/Cas9 genetic modification of CYP3A5*3 in HuH-7 human hepatocyte cell line leads to cell lines with increased midazolam and tacrolimus metabolism. Drug Metab Dispos 45:957–65.
   PubMed Web of Science ®Google Scholar
• Ernest II CS, Hall SD, Jones DR. (2005). Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 12:583–91.
   Google Scholar
• Feld JJ, Moreno C, Trinh R, et al. (2016). Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol 64:301–7.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. (2014). ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. New Engl J Med 370:1983–92.
   PubMed Web of Science ®Google Scholar
• Granfors MT, Wang J, Kajosaari LI, et al. (2006). Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98:79–85.
   PubMed Web of Science ®Google Scholar
• Hezode C, Asselah T, Reddy KR, et al. (2015). Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced subjects with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomized, open-label trial. Lancet 385:2502–9.
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, et al. (2001). The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–9.
   PubMedGoogle Scholar
• Khatri A, Menon RM, Marbury TC, et al. (2015). Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. J Hepatol 63:805–12.
   PubMed Web of Science ®Google Scholar
• Koudriakova T, Iatsimirskaia E, Utkin I, et al. (1998). Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552–61.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. (2012). A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology 56:1515–6.
   Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. (2014). Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. New Engl J Med 370:222–32.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nate Genet 27:383–91.
   PubMed Web of Science ®Google Scholar
• Kumar GN, Rodrigues AD, Buko AM, Denissen JF. (1996). Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423–31.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Makara M, Akarca US, et al. (2015). Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology 149:971–80.
   PubMed Web of Science ®Google Scholar
• MacPhee IAM, Fredericks S, Tai T, et al. (2002). Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplatation 74: 1486–9.
   PubMed Web of Science ®Google Scholar
• Matsumoto J, Ariyoshi N, Ishii I, Kitada M. (2013). Functional characterization of seven single-nucleotide polymorphisms of the steroid sulfatase gene found in a Japanese population. J Hum Genet 58:267–72.
   PubMed Web of Science ®Google Scholar
• Menon RM, Klein CE, Podsadecki TJ, et al. (2016). Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol 81:929–40.
   PubMed Web of Science ®Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. (2015). Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77–87.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Kaltiala EH, Larmi TKI, Kärki NT. (1974). Cytochrome P450-linked monooxygenase system and drug induced spectral interactions in human liver microsomes. Chem Biol Interact 9:205–16.
   PubMed Web of Science ®Google Scholar
• Polepally AR, Badri PS, Eckert D, et al. (2017). Effects of mild and moderate renal impairment on ombitasvir, paritaprevir, ritonavir, dasabuvir, and ribavirin pharmacokinetics in patients with chronic HCV infection. Eur J Drug Metab Pharmacokinet 42:333–9.
   PubMed Web of Science ®Google Scholar
• Salmona M, Caporossi A, Simmonds P, et al. (2016). First next-generation sequencing full-genome characterization of a hepatitis C virus genotype 7 divergent subtype. Clin Microbiol Infect 22:947.e1–.e8.
   Web of Science ®Google Scholar
• Shen J, Serby M, Reed A, et al. (2016a). Metabolism and disposition of the hepatitis C protease inhibitor paritaprevir in humans. Drug Metab Dispos 44:1164–73.
   PubMed Web of Science ®Google Scholar
• Shen J, Serby M, Surber B, et al. (2016b). Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans. Drug Metab Dispos 44:1148–57.
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318–27.
   PubMed Web of Science ®Google Scholar
• Toshikuni N. (2017). Therapy with direct-acting antiviral agents for hepatitis C-related liver cirrhosis. Gut Liver 11:335–48.
   PubMed Web of Science ®Google Scholar
• Tseng E, Walsky RL, Luzietti RA Jr, et al. (2014). Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug Metab Dispos 42:1163–73.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Hyland R, et al. (2012). Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40:686–97.
   Web of Science ®Google Scholar
• Wojnowski L. (2004). Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26:192–9.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. (2014). Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J Med 370:1604–14.
   PubMed Web of Science ®Google Scholar